Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Biologics
  4.  » 
  5. Drug Product CDMO Services
  6.  » Formulation Development

Formulation Development

A formulation laboratory with large machineryOur comprehensive formulation development capabilities ranging from pre-clinical through commercialization, combined with our product-centric approach ensure faster delivery of a stable product. The development team will integrate the biophysical and biochemical characterization of your molecule with the final product format, developing the best formulation of your product for your patient.

Back to top

MODALITIES & DOSAGE FORMS

WIDE RANGE OF MOLECULESMULTIPLE PRODUCT PRESENTATIONS

Monoclonal, bi/tri-specific antibodies
Oligonucleotides
Recombinant proteins
Fusion proteins
Peptides
Antibody fragments
Small molecule entities
Adsorbed vaccines
Conjugated vaccines
mRNA-LNP

Liquid formulations
High viscosity solutions
Liquid suspensions
Lyophilized drug product
DP placebo and diluent
Vials / prefilled syringes / cartridges

Back to top

TECHNOLOGY & METHODS

  • Molecule developability
    • Hot spot analysis (primary sequence based manual or in-silico prediction)
    • Forced degradation
    • Post translational modification and impurity characterization (high resolution LC-MS)
    • Stability and solubility predicting assays
  • Colloidal and conformational stability
    • A2, B22, kD determination by high throughput DLS and SLS analysis
    • Tm, Tagg by capillary DSC and DSF
    • ΔG by ICD
  • Protein content analysis (UV/Visible)
    • Absorbance spectrophotometry (microfluidic, microplate, cuvette)
    • Slope spectroscopy (SoloVPE)
  • Size variants (aggregates and fragments)
    • SEC-UHPLC and SEC-HPLC (PDA, FLR, CAD, and QDa detectors)
    • High throughput and high-resolution CE-SDS (microfluidic chip and capillary based)
  • Charge variants
    • IEX-HPLC (cation and anion exchange)
    • High throughput and high resolution icIEF (capillary)
    • CZE (microfluidic chip)
  • Potency assay by binding ELISA, BLI and ITC
  • Subvisible particle characterization
    • MFI, BMI, LO and optical and florescence microscopy
  • Advanced biophysical protein characterization
    • Molecular Size by EAF4, AUC
    • Secondary structure by DSC, CD
  • Biochemical product characterization
    • Solution pH, viscosity, density, and osmolality
    • Thermal analysis – Tc, Teu, Tg’ with mDSC, FDM, DTA and impedance analyzer
    • Residual moisture by KF
  • Automated bioprocessing
    • Microvolume liquid handing (dilution, dispensing, transfer – plates, tubes, vials)
    • Buffer exchange (plate, tube)

Catalent Biologics’ drug product development centers in Bloomington, Indiana, USA and Limoges, France provide integrated solutions for development and manufacturing reducing risks and accelerating programs towards and through the clinic, and ultimately to market, as well as stand-alone formulation development services.

See also: